Jazz Pharmaceuticals (NASDAQ:JAZZ) Updates FY24 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $19.50-20.60 for the period, compared to the consensus earnings per share estimate of $19.51. The company issued revenue guidance of $4.0-4.1 billion, compared to the consensus revenue estimate of $4.04 billion.

Jazz Pharmaceuticals Stock Up 0.1 %

NASDAQ:JAZZ traded up $0.12 during midday trading on Wednesday, reaching $111.55. The company had a trading volume of 800,619 shares, compared to its average volume of 668,778. The stock’s fifty day simple moving average is $110.51 and its 200-day simple moving average is $109.60. The firm has a market capitalization of $6.89 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.38 and a beta of 0.57. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $134.48. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36.

Analysts Set New Price Targets

A number of analysts have recently commented on JAZZ shares. Piper Sandler cut their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company dropped their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Royal Bank of Canada increased their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.43.

Insider Transactions at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.